My Market Wizard

GSK plc 6-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

GSK plc
,

Filing date:

02/21/2025

TLDR:

GSK plc reports the vesting of performance share plan awards to PDMRs and their PCAs, along with subsequent sales to cover tax liabilities.

ELI5:

GSK gave some of its executives shares as part of their compensation, and now those shares are becoming fully owned by the executives. Some of these executives are selling some of the shares to pay taxes.

Accession #:

0001654954-25-001742

Published on

Analyst Summary

  • Performance Share Plan awards granted in 2022 vested on February 18, 2025.
  • Vesting was based on business performance conditions over a three-year period from January 1, 2022, to December 31, 2024.
  • Vested shares for Executive Directors are subject to an additional two-year vesting period.
  • A portion of the award made to each PDMR and PCA has lapsed.
  • PDMRs and PCAs sold shares to meet tax liabilities.
  • Closing prices of Ordinary Shares and ADSs of GSK plc on the vesting date were £14.43 and $36.61, respectively.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️